Context: The Union Health Ministry has prohibited the use of all Fixed-Dose Combinations (FDCs) containing chlorpheniramine maleate and phenylephrine hydrochloride in children below four years, citing concerns over adverse effects, dosing risks and inadequate evidence of efficacy.
About Fixed-Dose Combinations (FDCs)
- Definition: An FDC is a medicine containing two or more active pharmaceutical ingredients in a fixed ratio in a single dosage form.
- Potential Benefits: FDCs can improve patient convenience, treatment adherence and therapeutic effectiveness when the combination is scientifically justified.
- Risks: Irrational FDCs can cause unnecessary drug exposure, adverse reactions, drug interactions and difficulty in adjusting individual doses, making them particularly concerning for children.
- Irrational FDCs: An FDC may be considered irrational when its ingredients lack adequate evidence of combined efficacy, appropriate dosage or therapeutic advantage over individual medicines.
Why Were These FDCs Restricted?
- Chlorpheniramine Maleate: An antihistamine used for runny nose and sneezing; in young children, it may cause marked drowsiness or paradoxical excitability.
- Phenylephrine Hydrochloride: A decongestant used for nasal blockage, but can affect heart rate and blood pressure, posing risks to young children.
- Paediatric Vulnerability: Children below four are more susceptible to dosing errors and adverse drug reactions, while the therapeutic benefit of these combinations does not sufficiently justify the associated risks.
Regulatory Measures
- Age Restriction: All FDC formulations containing these two ingredients are prohibited for use in children below four years.
- Mandatory Warning: Manufacturers must prominently display “Fixed Dose Combination shall not be used in children below four years of age” on labels, package inserts and promotional literature.
- Expanded Restriction: Earlier, in 2023, warnings applied only to certain formulations; the latest measure extends the restriction to all FDCs containing these ingredients.
- International Alignment: The measure is consistent with paediatric safety safeguards adopted by regulatory authorities in the United States and Australia.
Drug Regulation in India
- Drugs and Cosmetics Act, 1940: The principal legislation governing the import, manufacture, distribution and sale of drugs and cosmetics in India.
- Drugs and Cosmetics Rules, 1945: Provide detailed regulatory requirements relating to licensing, standards, labelling, manufacturing and sale of drugs and cosmetics.
- Central Drugs Standard Control Organization (CDSCO): India's national regulatory authority for drugs and medical devices, functioning under the Ministry of Health and Family Welfare and headed by the Drugs Controller General of India (DCGI).
- Drugs Technical Advisory Board (DTAB): The highest statutory technical advisory body under the Drugs and Cosmetics Act, advising the Central and State Governments on technical matters concerning drugs and cosmetics.
- Central Government's Prohibition Power: Under Section 26A of the Drugs and Cosmetics Act, 1940, the Central Government can regulate, restrict or prohibit the manufacture, sale or distribution of a drug in the public interest when it poses risks or lacks therapeutic value.
- State Drug Control Authorities: States primarily regulate the manufacture, sale and distribution of drugs through their respective drug-control administrations, while the Centre exercises important functions through CDSCO.
Legal and Institutional Framework
- Expert Assessment: The present restriction follows recommendations from an expert committee and DTAB, demonstrating the role of scientific and technical assessment in pharmaceutical regulation.
- Pharmacovigilance: India monitors adverse drug reactions through the Pharmacovigilance Programme of India (PvPI), which seeks to identify, assess and prevent adverse effects associated with medicines.
Significance: The measure strengthens paediatric drug safety and rational medicine use by limiting potentially harmful combinations, while placing greater responsibility on pharmaceutical manufacturers to ensure evidence-based formulations and appropriate labelling.
